InvestorsHub Logo
Followers 71
Posts 7941
Boards Moderated 0
Alias Born 01/29/2015

Re: None

Saturday, 03/25/2023 2:55:20 AM

Saturday, March 25, 2023 2:55:20 AM

Post# of 16696
Let's put the "Trust" and "Confidence" theory to a test.

Trust is the belief that the person to be trusted would act as the trusting person would in that situation.

Confidence is related to factors such as competence or past performance.

Trust builds Confidence.

Thus far, Moreau (CEO0 started out with 40 million shares of Breathtec Biomedical. Those shares have since turned into 4 billion split adjusted Algernon shares. I've previously laid out the math.

A 100:1 reverse split happened due to the CEO begging shareholders to believe him that a Nasdaq uplisting was necessary and imminent for the company's survival. Wall Street experts gave Algernon Pharmaceuticals a resounding vote of NO CONFIDENCE.

The COVID-19 clinical trials were diversions/excursions from the targeted pipeline and secured massive dilution right out of the gate for shareholders - the covid scheme coughed up more than 100% dilution for two demonstrably failed studies in South Korea and Romania.

The CEO abandoned the FAIMS technology after stating in black and white the program would continue irrespective of having gone down the repurposed drugs path. He back peddled on that claim shortly thereafter.

By the way, that FAIMS “Research Only" angle abandoned by Algernon is now being peddled by Cannabix Technologies. The exact same FAIMS technology advanced by the monetary partnership ($$$) between Cannabix and Algernon will only have one possible winner to the agreement no less credited to Algernon’s haphazard management decisions.

Meanwhile, AlphaNorth (a small Canadian investment outfit) is gobbling up the company right before your eyes. They'll likely own somewhere north of 20% of Algernon in short order. Dilution has been their best friend (BFF) and there’s lots more where that came from friends.

There are now 3 separate and unequal pots of shares (AGN/PF, AGN Neuro, AGN.RT) that attempt to camouflage the insane amount of dilution since the 100:1 reverse split. It's been a 300% increase in shares since ^that split.

There are ZERO known plans to raise capital for ANY clinical trial for Algernon Pharmaceuticals. Keep in mind, there are no clinical trials being conducted by Algernon. The only trial happening is a Phase 1 at the "Private" subsidiary company for DMT.

What you are getting beyond dilution is Moreau prancing and dancing around clown town spouting about DMT. That is all.

Moreau also encouraged you to buy shares of the "private" company. That doesn't project confidence in the direction of AGN/PF shares.

They are struggling now to keep the lights on at their virtual corporate office but their salaries and bonuses have not suffered or sacrificed in the least bit.

No one has disputed any of the math.

No one has disputed the fact Moreau endorsed neo-Nazi Chris Temple's "Immediate Buy" opinion of the stock 6 months ago. Chris Temple is a neo-Nazi wearing black suspenders with a Nazi logo. He's standing directly behind the neo-Nazi leader carrying the American flag.

https://investorshub.advfn.com/uimage/uploads/2023/3/25/qkqylChris_Temple_-_neo-Nazi.jpg

^This is not a personal attempt to offend anyone here. It’s an attempt to make you aware of the type of reckless decisions being made by a publicly/globally traded penny stock company. You deserve the right to know. If Algernon management doesn’t want you to know what they stand for or against, they should take the entire company private. It seems to be headed in that direction anyway as time rolls bye bye.

No one has disputed the fact Algernon's CEO (Moreau), CSO (Williams), CFO (Sadhra) ALL orchestrated a blatant, and should be criminal, conflict of interest by working for Kulwant Malhi at failed (bankrupt) First Responder Technologies. Malhi was flipping shares of AGN/PF by the millions and walked away with somewhere around 10 Million Dollars at the time shareholders were losing all their money with falling stock prices that never recovered.

The above is merely a handful of "Trust" and "Confidence" issues.

A proclaimed buy-in of AGN.RT by anyone means they're a Canadian investor. The news flash here is - most are not eligible to participate in this latest dilution scheme.

The price of the "Rights Offering" shares are equal to 18 cents with a matching warrant.

Shares of AGNPF (USA shareholders) would need to trade at 9 Cent to match the Rights Offering by Algernon Pharmaceuticals Inc.

It would appear that sub 10 cent shares of AGNPF is not out of the realm of possibility.

If you took the closing price of today's Market Cap and divided it by the true number of outstanding shares, this would be the true price of all the shares:

AGN/PF - 10 Million shares

AGN Neuro - 20 Million shares

AGN.RT - 10 Million shares

Total Shares - 40 Million

Algernon Pharmaceuticals Inc - Market Cap $2,658,000

Divide the Market Cap by 40 Million.

2,658,000/40,000,000 = 6 Cent

6 Cent (.06) is where the true price of all shares should fall.

All ^that and I didn't even mention the "Trust" and "Confidence" 55% and 65% Chance of Success claims pumped to the masses with Biopub webinars.

Hey Mag...how about that PPCB? See any type of "Trust" or "Confidence" comparisons to AGN/PF?

Maybe it all depends on where one's time and money fits into the narrative in order to see the entire picture versus a snapshot huh? What I've stated here barely scratches the surface of Algernon's man-made Dante's Inferno.


AGN/PF Splits

Oct 17, 2018 - 2/1 Reverse Split

Nov 24, 2021 - 100/1 Reverse Split

Mar 3, 2023 - 4/1 Forward Split


Minimum Break Even Share Price

$7.50 USD

As I’ve stated before, by the time Algernon gets to any significantly compelling data, the Market Cap may require a Multi-Billion dollar valuation for Reverse Split shareholders to break even, if ever.

On Another Note...without getting too long-winded, I’ll drop that one here tomorrow (Sunday).


M$